Skip to content

OUR SOLUTION

The Expedited Innovation Platform (EIP)

Transforming Validated IP into Exit-Ready Assets Within 18–30 Months

Traditional healthcare innovation takes too long and carries too much risk. The EIP is Promptus’ proprietary process that accelerates the journey from discovery to acquisition, ensuring the best technologies don’t die in labs — they reach the market quickly, efficiently, and with certainty.

The EIP Process

Discover

AI-Driven IP Evaluation & Scoring
We start with deep market and trend analysis to identify the highest-potential sectors and assets. Our AI-driven discovery process screens IP against three critical criteria:
  • Clear pathways to strong, defensible patents
  • FDA Class II regulatory fit (avoiding drugs or high-risk devices)
  • Strong business case with sustainable margins
  • Early mapping of potential acquirers and licensors

Acquire

Secure & Protect IP
Once high-potential innovations are identified, we acquire and protect the IP through a structured patenting process — ensuring every asset has a secure foundation for commercialization and future exit.

Finance

Milestone-Based Funding
Each project is housed in its own stand-alone LLC/SPV (Special Purpose Vehicle). Promptus manages fundraising and allocates capital in milestone stages tied to measurable outcomes:
  • Scientific proof of concept
  • Technology beta development
  • Prototype and pre-commercial readiness
This model ensures efficient capital use, risk reduction, and investor confidence.

Build

Design, Engineer, Test & Prototype
We bring in industry specialists to accelerate product development with precision:
  • Rapid design and engineering
  • Specification design and documentation
  • Testing and quality assurance
  • Partnerships with manufacturers for prototypes
  • Delivery of functional schematics and prototypes ready for validation

Certify

FDA Clearance via 510(k)
Regulatory rigor is built into every stage of the EIP. Our team manages the entire FDA submission process:
  • Filing patents and protecting IP
  • Aligning development to FDA Class II design control requirements
  • Leveraging pre-submission meetings to streamline review
  • Conducting verification and validation testing to consensus standards
  • Managing FDA communications to ensure momentum and timely clearance

Exit

Positioning & Sale to Buyers
The exit strategy begins early, not at the end. From proof of concept, we actively position each technology for acquisition:
  • Using AI engines to identify potential buyers and portfolio gaps
  • Building branding and positioning around buyer needs
  • Marketing directly to identified acquisition partners
  • Leveraging PR to generate market demand
  • Closing transactions with previously identified partners